Dr. Orhun H. Kantarci, MD

Dr. Kantarci practices at Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota.

Dr. Kantarci's NPI, 1225015464, was assigned on December 29, 2005. Dr. Kantarci graduated from Istanbul University Fom in 1993. Dr. Kantarci's Minnesota license number on file is 45754.

Dr. Kantarci's primary practice is Mayo Clinic Breast Diagnostic Clinic, at 200 First Street SW, Rochester, MN 55905. The practice phone is (507) 284-5968.

Dr. Kantarci's primary practice is Mayo Clinic Breast Diagnostic Clinic in Rochester, Minnesota. Dr. Kantarci is also affiliated with Mayo Clinic Hospital, Saint Marys Campus. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Kantarci to 1 more clinical lab and 1 hospice, each named with a free account. Dr. Kantarci's employer is on file too: a breast imaging center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kantarci practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kantarci's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kantarci is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Kantarci has a license on file in Minnesota.

Dmand AI lists encephalopathy, hereditary polyneuropathy, multiple sclerosis, neuropathy and parkinson's disease among the conditions Dr. Kantarci treats.

CMS data shows 55 Medicare services from Dr. Kantarci across 4 procedure codes in 2024, all of them office visits, for 84 Medicare patients. Medicare paid $6,677 for them. Every service was in an office.

CMS counts 84 Medicare patients who saw Dr. Kantarci in 2024. The largest group is 65 to 74, with 48 patients. 63% of them have high cholesterol, and 54% have high blood pressure. 15% are also on Medicaid. Their average risk score is 1.53, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kantarci's median patient age at 55, with 70% women.

In 2024, Dr. Kantarci wrote 93 Medicare Part D claims for 26 patients. 74% of them were for generic drugs. CMS names the drug for 23 of them, across 2 drugs with 11 or more claims each, at $687,167 in total drug cost. In 2023, CMS named 73 claims across 5 drugs.

Dr. Kantarci accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kantarci as offering telehealth.

Dmand AI links 117 papers to Dr. Kantarci, published from 2010 to 2025. 2020 was the busiest year, with 11. The most frequent topics are Multiple Sclerosis, Disease Progression and Magnetic Resonance Imaging. Dr. Kantarci has published most often in Mult Scler. Dr. Kantarci's most frequent co-authors are Burcu Zeydan, MD, Brian G. Weinshenker, MD and Eoin Paul Flanagan, MBCHB.

Dmand AI links Dr. Kantarci to 1 clinical trial. Conditions studied include Multiple Sclerosis and Demyelinating Autoimmune Diseases, CNS.

CMS Open Payments shows 16 general payments to Dr. Kantarci from 3 drug and device companies from 2016 to 2018. Consulting fees make up the largest share, 73% of the total. Biogen, Inc. paid the most, $10,509.

Dr. Kantarci graduated from Istanbul University Fom in 1993. Dr. Kantarci is a member of AAN and AMA.

Dr. Kantarci is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.